Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
Bone Metastases
Brain Cancer
Business Management
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Genitourinary Cancers
Head & Neck Cancers
Hematologic Oncology
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Non-Hodgkin Lymphoma
Oncology Nursing News
Patient Resources
Sarcomas/TGCT
Special Reports in Personalized Cancer Care
Supportive Care
Online CME
Interactive Publications
SELECT A TOPIC
CURRENT VIEW
All Specialties
▲
Education ▲
Education ▼
Register
|
Login
Conference Coverage
Videos
NewsNetwork
OncLive
®
TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
More >>
OncLive TV: Michael K. Brawer, MD
<< Back to Our Featured Experts
Dr. Michael Brawer on Predicting Prostate Cancer Aggressiveness
Oncology Specialists
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
S. Yousuf Zafar, MD
Gregory Zagaja, MD
Jasmine Zain, MD
Jasmine M. Zain, MD
Tal Zaks, MD, PhD
Mark M. Zalupski, MD
Dmitriy Zamarin, MD, PhD
Dan Zandberg, MD
Hassane M. Zarour, MD
Kimberly J. Van Zee, MD
Kimberly Van Zee, MD
Andrew D. Zelenetz, MD, PhD
Tian Zhang, MD
Jingsong Zhang, MD, PhD
Andrew Zhu, MD, PhD
Viola W. Zhu, MD, PhD
You-cai Zhu, MD, PhD
Matthew R. Zibelman, MD
Oliver Zill
Ari Zimran, MD
Jeffrey Zonder, MD
Yu (Amy) Zong
Dieter Zopf
Jo Anne Zujewski, MD
Javier Zulueta, MD
Evolving HCC Treatment Paradigm: Combinations and Sequencing
Trending Now
Expanding the Treatment Toolbox in
ESR1
-Mutant Breast Cancer
FDA Waives ODAC Review of Luspatercept in MDS
Challenges Remain Amid Rapid Advances in AML
Novel Therapies Show Significant Activity in Relapsed/Refractory ALL
Publications
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
x
Subscribe